Page last updated: 2024-08-22

gadolinium and raltegravir potassium

gadolinium has been researched along with raltegravir potassium in 1 studies

Research

Studies (1)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	0 (0.00)	29.6817
2010's	1 (100.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Adiutori, R; Altmann, D; Bianchi, L; Christensen, T; Giovannoni, G; Gold, J; Holden, D; MacManus, D; Marta, M; Meier, UC; Miller, D; Schmierer, K; Turner, B; Yousry, T	1

Trials

1 trial(s) available for gadolinium and raltegravir potassium

Article	Year
A phase II baseline versus treatment study to determine the efficacy of raltegravir (Isentress) in preventing progression of relapsing remitting multiple sclerosis as determined by gadolinium-enhanced MRI: The INSPIRE study. Multiple sclerosis and related disorders, 2018, Volume: 24 Topics: Adult; Contrast Media; Disease Progression; Female; Gadolinium; HIV Integrase Inhibitors; Humans; Magnetic Resonance Imaging; Male; Multiple Sclerosis, Relapsing-Remitting; Neuroprotective Agents; Raltegravir Potassium; Treatment Failure	2018

Article

Year

A phase II baseline versus treatment study to determine the efficacy of raltegravir (Isentress) in preventing progression of relapsing remitting multiple sclerosis as determined by gadolinium-enhanced MRI: The INSPIRE study.

Multiple sclerosis and related disorders, 2018, Volume: 24

Topics: Adult; Contrast Media; Disease Progression; Female; Gadolinium; HIV Integrase Inhibitors; Humans; Magnetic Resonance Imaging; Male; Multiple Sclerosis, Relapsing-Remitting; Neuroprotective Agents; Raltegravir Potassium; Treatment Failure

2018